Page last updated: 2024-08-03 08:41:16
9-(tetrahydro-2-furyl)-adenine
Description
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 22879197 |
| SCHEMBL ID | 8712264 |
| MeSH ID | M0068772 |
Synonyms (8)
| Synonym |
|---|
| nsc 53339 |
| 9-(tetrahydro-2-furyl)-adenine |
| sq-22,536 |
| SCHEMBL8712264 |
| NCGC00389211-01 |
| 9-[(2r)-oxolan-2-yl]purin-6-amine |
| adenine, 9-(tetrahydro-2-furanyl)-(8ci) |
| DTXSID201017381 |
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
Research
Studies (267)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 16 (5.99) | 18.7374 |
| 1990's | 47 (17.60) | 18.2507 |
| 2000's | 143 (53.56) | 29.6817 |
| 2010's | 57 (21.35) | 24.3611 |
| 2020's | 4 (1.50) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 274 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| gamma-aminobutyric acid | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid | human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule | 1996 | 2014 | 21.5 | low | 0 | 0 | 2 | 1 | 1 | 0 |
| adenine | | 6-aminopurines;
purine nucleobase | Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 1980 | 2021 | 20.2 | high | 0 | 16 | 64 | 131 | 52 | 1 |
| agmatine | | guanidines;
primary amino compound | Escherichia coli metabolite;
mouse metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ammonium hydroxide | | azane;
gas molecular entity;
mononuclear parent hydride | EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cadaverine | | alkane-alpha,omega-diamine | Daphnia magna metabolite;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| choline | | cholines | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlorine | | halide anion;
monoatomic chlorine | cofactor;
Escherichia coli metabolite;
human metabolite | 1991 | 2011 | 19.8 | low | 0 | 0 | 1 | 7 | 1 | 0 |
| hydrogen sulfide | | gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride | Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| dimethyl sulfoxide | | sulfoxide;
volatile organic compound | alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| glycine | | alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical | 2000 | 2001 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| glycerol | | alditol;
triol | algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| histamine | | aralkylamino compound;
imidazoles | human metabolite;
mouse metabolite;
neurotransmitter | 2001 | 2006 | 20.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| melatonin | | acetamides;
tryptamines | anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrites | | monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species | human metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| spermine | | polyazaalkane;
tetramine | antioxidant;
fundamental metabolite;
immunosuppressive agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| urea | | isourea;
monocarboxylic acid amide;
one-carbon compound | Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 2-amino-5-phosphonovalerate | | non-proteinogenic alpha-amino acid | NMDA receptor antagonist | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 8-hydroxy-2-(di-n-propylamino)tetralin | | phenols;
tertiary amino compound;
tetralins | serotonergic antagonist | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gallopamil | | benzenes;
organic amino compound | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| sk&f-38393 | | benzazepine;
catechols;
secondary amino compound | | 2006 | 2010 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 1,3-dipropyl-8-cyclopentylxanthine | | oxopurine | adenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-anilino-8-naphthalenesulfonate | | aminonaphthalene;
naphthalenesulfonic acid | fluorescent probe | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| edelfosine | | glycerophosphocholine | | 2004 | 2006 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| n-(3-(aminomethyl)benzyl)acetamidine | | aralkylamine;
carboxamidine;
primary amino compound | angiogenesis inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one | | oxadiazoloquinoxaline | EC 4.6.1.2 (guanylate cyclase) inhibitor | 2000 | 2019 | 17.3 | low | 0 | 0 | 2 | 12 | 4 | 0 |
| 2-aminoethoxydiphenyl borate | | organoboron compound;
primary amino compound | calcium channel blocker;
IP3 receptor antagonist;
potassium channel opener | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3-aminobenzamide | | benzamides;
substituted aniline | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3-bromo-7-nitroindazole | | | | 2002 | 2010 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| meglutol | | 3-hydroxy carboxylic acid;
dicarboxylic acid;
tertiary alcohol | anticholesteremic drug;
antimetabolite;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
human metabolite;
plant metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-aminopyridine | | aminopyridine;
aromatic amine | avicide;
orphan drug;
potassium channel blocker | 2005 | 2011 | 15.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ethylisopropylamiloride | | aromatic amine;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines;
tertiary amino compound | anti-arrhythmia drug;
neuroprotective agent;
sodium channel blocker | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 8-(4-sulfophenyl)theophylline | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tyrphostin a23 | | catechols | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| tyrphostin 25 | | benzenetriol | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| albuterol | | phenols;
phenylethanolamines;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| aluminum fluoride | | aluminium coordination entity | | 1996 | 1997 | 27.7 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| am 251 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
organoiodine compound;
pyrazoles | antidepressant;
antineoplastic agent;
apoptosis inducer;
CB1 receptor antagonist | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminoglutethimide | | dicarboximide;
piperidones;
substituted aniline | adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pimagedine | | guanidines;
one-carbon compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| theophylline | | dimethylxanthine | adenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent | 1987 | 2001 | 29.2 | low | 0 | 1 | 1 | 2 | 0 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 1986 | 2017 | 22.0 | low | 0 | 1 | 1 | 1 | 1 | 0 |
| baclofen | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound | central nervous system depressant;
GABA agonist;
muscle relaxant | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bay-k-8644 | | (trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester | | 1990 | 1996 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| bisindolylmaleimide i | | | | 1997 | 2016 | 21.0 | low | 0 | 0 | 2 | 2 | 1 | 0 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 1990 | 2013 | 23.0 | low | 0 | 0 | 2 | 0 | 1 | 0 |
| calmidazolium | | imidazolium ion | apoptosis inducer;
calmodulin antagonist | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| carbonyl cyanide m-chlorophenyl hydrazone | | hydrazone;
monochlorobenzenes;
nitrile | antibacterial agent;
geroprotector;
ionophore | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cgp 12177 | | aromatic ether;
benzimidazoles;
secondary alcohol;
secondary amino compound | beta-adrenergic antagonist | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chelerythrine | | benzophenanthridine alkaloid;
organic cation | antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| clenbuterol | | amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clonidine | | clonidine;
imidazoline | | 1997 | 1999 | 26.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| cyproheptadine | | piperidines;
tertiary amine | anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| amphetamine | | primary amine | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ddt | | benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide | bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiorphan | | N-acyl-amino acid | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| berotek | | resorcinols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 2005 | 2006 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| flutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide | androgen antagonist;
antineoplastic agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 1996 | 2011 | 18.1 | low | 0 | 0 | 1 | 5 | 1 | 0 |
| 1-(5-isoquinolinesulfonyl)-2-methylpiperazine | | isoquinolines;
N-sulfonylpiperazine | EC 2.7.11.13 (protein kinase C) inhibitor | 1996 | 2005 | 24.0 | low | 0 | 0 | 2 | 2 | 0 | 0 |
| ha 1004 | | isoquinolines | | 1996 | 2002 | 26.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| ibudilast | | pyrazolopyridine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 1990 | 2015 | 20.1 | low | 0 | 0 | 2 | 5 | 1 | 0 |
| 1-methyl-3-isobutylxanthine | | 3-isobutyl-1-methylxanthine | | 1986 | 2020 | 25.8 | low | 0 | 4 | 9 | 7 | 1 | 0 |
| isoguvacine | | tetrahydropyridine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 1986 | 2016 | 24.2 | low | 0 | 1 | 4 | 6 | 1 | 0 |
| losartan | | biphenylyltetrazole;
imidazoles | angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | | chromones;
morpholines;
organochlorine compound | autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 6-anilino-5,8-quinolinedione | | aminoquinoline;
aromatic amine;
p-quinones;
quinolone | antineoplastic agent;
EC 4.6.1.2 (guanylate cyclase) inhibitor | 1997 | 2010 | 21.0 | low | 0 | 0 | 2 | 2 | 0 | 0 |
| metoprolol | | aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound | antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| milrinone | | bipyridines;
nitrile;
pyridone | cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2003 | 2016 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| molsidomine | | ethyl ester;
morpholines;
oxadiazole;
zwitterion | antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent | 2000 | 2001 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| ethylmaleimide | | maleimides | anticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenamic acid | | aminobenzoic acid;
secondary amino compound | membrane transport modulator | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 1990 | 2013 | 22.2 | low | 0 | 0 | 5 | 4 | 2 | 0 |
| nimesulide | | aromatic ether;
C-nitro compound;
sulfonamide | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| nitrendipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester | antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent | 1990 | 2001 | 28.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| npc 15437 | | | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 5-nitro-2-(3-phenylpropylamino)benzoic acid | | nitrobenzoic acid | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ns 2028 | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ns 1619 | | (trifluoromethyl)benzenes;
benzimidazoles;
phenols | potassium channel opener | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| octopamine | | phenylethanolamines;
tyramines | neurotransmitter | 2005 | 2014 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fenclonine | | phenylalanine derivative | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pd 98059 | | aromatic amine;
monomethoxyflavone | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 2001 | 2008 | 18.2 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| pinacidil | | pyridines | | 1997 | 2000 | 25.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| potassium chloride | | inorganic chloride;
inorganic potassium salt;
potassium salt | fertilizer | 1993 | 2008 | 20.5 | low | 0 | 0 | 1 | 7 | 0 | 0 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| probucol | | dithioketal;
polyphenol | anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| procaterol | | quinolines | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propidium | | phenanthridines;
quaternary ammonium ion | fluorochrome;
intercalator | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 1986 | 2003 | 27.0 | low | 0 | 1 | 0 | 2 | 0 | 0 |
| pyrilamine | | aromatic ether;
ethylenediamine derivative | H1-receptor antagonist | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | | methoxybenzenes | | 1983 | 2001 | 31.8 | low | 0 | 2 | 1 | 1 | 0 | 0 |
| rolipram | | pyrrolidin-2-ones | antidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 1987 | 2020 | 21.3 | low | 0 | 1 | 1 | 3 | 1 | 0 |
| sarpogrelate | | hemisuccinate;
stilbenoid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| linsidomine | | morpholines | | 2000 | 2001 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| sodium fluoride | | fluoride salt | mutagen | 1991 | 2008 | 24.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| suramin | | naphthalenesulfonic acid;
phenylureas;
secondary carboxamide | angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tyramine | | monoamine molecular messenger;
primary amino compound;
tyramines | EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| w 7 | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| corticosterone | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 1999 | 2002 | 23.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| thymidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbachol | | ammonium salt;
carbamate ester | cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic | 1996 | 2004 | 24.2 | low | 0 | 0 | 3 | 1 | 0 | 0 |
| spironolactone | | 3-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester | aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aldosterone | | 11beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde | human metabolite;
mouse metabolite | 2000 | 2004 | 22.6 | low | 0 | 0 | 2 | 3 | 0 | 0 |
| etiocholanolone | | 17-oxo steroid;
3alpha-hydroxy steroid;
androstanoid | human metabolite;
mouse metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triiodothyronine | | 2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine | human metabolite;
mouse metabolite;
thyroid hormone | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| serine | | L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| adenosine diphosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate | fundamental metabolite;
human metabolite | 1982 | 2010 | 25.6 | low | 0 | 1 | 2 | 2 | 0 | 0 |
| bromodeoxyuridine | | pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| phenylephrine | | phenols;
phenylethanolamines;
secondary amino compound | alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent | 1991 | 2006 | 23.8 | low | 0 | 0 | 2 | 2 | 0 | 0 |
| edetic acid | | ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid | anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tyrosine | | amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adenosine monophosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate | adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylalanine | | amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid | algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| desoxycorticosterone | | 20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cycloheximide | | antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol | anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor | 1996 | 2011 | 21.7 | low | 0 | 0 | 2 | 0 | 1 | 0 |
| egtazic acid | | diether;
tertiary amino compound;
tetracarboxylic acid | chelator | 1996 | 2010 | 19.2 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| ornithine | | non-proteinogenic L-alpha-amino acid;
ornithine | algal metabolite;
hepatoprotective agent;
mouse metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| valine | | L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| tert-butylhydroperoxide | | alkyl hydroperoxide | antibacterial agent;
oxidising agent | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| phencyclidine | | benzenes;
piperidines | anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bis(p-chlorophenyl)acetic acid | | monocarboxylic acid;
monochlorobenzenes | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinoxalines | | mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene | | 2000 | 2019 | 17.3 | low | 0 | 0 | 2 | 12 | 4 | 0 |
| phenidone | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| xanthenes | | xanthene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triethylene glycol dimethacrylate | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrroles | | pyrrole;
secondary amine | | 1997 | 2019 | 18.5 | low | 0 | 0 | 4 | 7 | 2 | 0 |
| framycetin | | aminoglycoside | allergen;
antibacterial drug;
Escherichia coli metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pregnenolone | | 20-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
C21-steroid | human metabolite;
mouse metabolite | 1999 | 2002 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| yohimbine | | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | alpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist | 1985 | 2014 | 24.5 | low | 0 | 1 | 0 | 0 | 1 | 0 |
| 2-chloroadenosine | | purine nucleoside | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| catechin | | catechin | antioxidant;
plant metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quinazolines | | azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines | | 1982 | 2001 | 32.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| indazoles | | indazole | | 2002 | 2010 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| cyclopentane | | cycloalkane;
cyclopentanes;
volatile organic compound | non-polar solvent | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxazoles | | 1,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 1997 | 2009 | 19.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2006 | 2013 | 14.8 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| muscarine | | monosaccharide | | 2001 | 2002 | 22.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| hydrazine | | azane;
hydrazines | EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| citrulline | | amino acid zwitterion;
citrulline | Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| bicuculline | | benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines | agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| kainic acid | | dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid | antinematodal drug;
excitatory amino acid agonist | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| dihydrotestosterone | | 17beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid | androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite | 2002 | 2011 | 17.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| gluconic acid | | gluconic acid | chelator;
Penicillium metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| copper gluconate | | organic molecular entity | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| durapatite | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| amiloride | | aromatic amine;
guanidines;
organochlorine compound;
pyrazines | diuretic;
sodium channel blocker | 1991 | 2000 | 28.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| cyclic cmp | | 3',5'-cyclic pyrimidine nucleotide | human metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| denatonium benzoate | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| dideoxyadenosine | | adenosines;
purine 2',3'-dideoxyribonucleoside | EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor | 1990 | 2013 | 21.5 | low | 0 | 0 | 4 | 5 | 1 | 0 |
| vidarabine | | beta-D-arabinoside;
purine nucleoside | antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| manganese | | elemental manganese;
manganese group element atom | Escherichia coli metabolite;
micronutrient | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gadolinium | | f-block element atom;
lanthanoid atom | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cesium chloride | | inorganic caesium salt;
inorganic chloride | phase-transfer catalyst;
vasoconstrictor agent | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| vasotocin | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| barium chloride | | barium salt;
inorganic chloride | potassium channel blocker | 2006 | 2011 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mopidamol | | dialkylarylamine;
tertiary amino compound | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| eedq | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetradecanoylphorbol acetate | | acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester | antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator | 1990 | 2005 | 24.8 | low | 0 | 0 | 3 | 2 | 0 | 0 |
| fluorides | | halide anion;
monoatomic fluorine | | 1996 | 1997 | 27.7 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| bromocriptine | | indole alkaloid | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 8-bromo cyclic adenosine monophosphate | | 3',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound | antidepressant;
protein kinase agonist | 1986 | 2020 | 21.1 | low | 0 | 1 | 6 | 15 | 2 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 2000 | 2001 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| adenosine diphosphate ribose | | ADP-sugar | Escherichia coli metabolite;
mouse metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| substance p | | peptide | neurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent | 1988 | 2011 | 27.3 | low | 0 | 1 | 1 | 0 | 1 | 0 |
| phorbol 12,13-dibutyrate | | butyrate ester;
phorbol ester;
tertiary alpha-hydroxy ketone | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| diltiazem | | 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2010 | 2017 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ng-nitroarginine methyl ester | | alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor | 2000 | 2015 | 18.7 | low | 0 | 0 | 1 | 10 | 1 | 0 |
| colforsin | | acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol | adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist | 1985 | 2020 | 22.1 | low | 0 | 6 | 19 | 27 | 8 | 0 |
| dazoxiben | | | | 1982 | 1986 | 40.0 | low | 0 | 4 | 0 | 0 | 0 | 0 |
| quinpirole | | pyrazoloquinoline | dopamine agonist | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mifepristone | | 3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound | abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fura-2 | | | | 1997 | 2011 | 20.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| mibefradil | | tetralins | T-type calcium channel blocker | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adenosine | | adenosines;
purines D-ribonucleoside | analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent | 1986 | 2014 | 23.1 | low | 0 | 2 | 2 | 8 | 1 | 0 |
| vanadates | | trivalent inorganic anion;
vanadium oxoanion | EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiazolyl blue | | organic bromide salt | colorimetric reagent;
dye | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| epigallocatechin gallate | | flavans;
gallate ester;
polyphenol | antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2',5'-dideoxyadenosine | | deoxyribonucleoside | | 1990 | 2013 | 22.6 | low | 0 | 0 | 2 | 2 | 1 | 0 |
| triazoles | | 1,2,3-triazole | | 2002 | 2014 | 16.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| carbonyl cyanide phenylhydrazone | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cromakalim | | | | 1997 | 2006 | 23.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| 4-o-methyl-12-o-tetradecanoylphorbol 13-acetate | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5'-adenylyl (beta,gamma-methylene)diphosphonate | | nucleoside triphosphate analogue | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| alpha,beta-methyleneadenosine 5'-triphosphate | | nucleoside triphosphate analogue | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| hydroxyisohexyl 3-cyclohexene carboxaldehyde | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 8-((4-chlorophenyl)thio)cyclic-3',5'-amp | | 3',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
aryl sulfide;
organochlorine compound | protein kinase agonist | 1997 | 2002 | 24.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| melanotan-ii | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diosgenin | | 3beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal | antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 11-ketoetiocholanolone | | 3-hydroxy steroid | androgen | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fulvestrant | | 17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide | antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| u 73122 | | aromatic ether;
aza-steroid;
maleimides | EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor | 1997 | 2016 | 19.1 | low | 0 | 0 | 4 | 10 | 3 | 0 |
| sr141716 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles | anti-obesity agent;
appetite depressant;
CB1 receptor antagonist | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluo-3 | | xanthene dye | fluorochrome | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fura-2-am | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bremazocine | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| arginyl-glycyl-aspartyl-serine | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,9-dideoxyforskolin | | acetate ester;
labdane diterpenoid;
organic heterotricyclic compound | plant metabolite | 1996 | 2009 | 22.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| n(g)-iminoethylornithine | | L-alpha-amino acid | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| kt 5823 | | gamma-lactam;
hemiaminal;
indolocarbazole;
methyl ester;
organic heterooctacyclic compound | EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor | 2004 | 2018 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| n-(1-methyl-2-phenylethyl)adenosine | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| way 100135 | | piperazines | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-(2,3-dicarboxycyclopropyl)glycine | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| amarogentin | | monosaccharide derivative;
secoiridoid glycoside | EC 5.99.1.2 (DNA topoisomerase) inhibitor;
metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ah 6809 | | xanthones | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| luzindole | | acetamides;
indoles | melatonin receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| peroxynitrous acid | | nitrogen oxoacid | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| angiotensin ii, des-phe(8)- | | amino acid zwitterion;
angiotensin | vasodilator agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone | | dichlorobenzene;
differentiation-inducing factor;
monomethoxybenzene;
resorcinols | eukaryotic metabolite;
signalling molecule | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rmi 12330a | | | | 1985 | 2018 | 20.4 | medium | 0 | 1 | 4 | 5 | 3 | 0 |
| bq 610 | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zd 7288 | | | | 2005 | 2018 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| dibutyryl cyclic-3',5'-cytidine monophosphate | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amthamine | | thiazoles | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-(3,4-dibutoxybenzyl)-2-imidazolidinone | | | | 1986 | 2002 | 30.0 | medium | 0 | 1 | 0 | 1 | 0 | 0 |
| omega-n-methylarginine | | amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid | | 2000 | 2010 | 20.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| dk-ah 268 | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 8-chloroadenosine-3',5'-cyclic monophosphorothioate | | | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| butoxamine | | | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diphloretin phosphate | | | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| xamoterol | | morpholines | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2'-deoxy-3'-adenosine monophosphate | | 2'-deoxyadenosine phosphate;
purine 2'-deoxyribonucleoside 3'-monophosphate | | 1997 | 1997 | 27.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| angiotensin ii | | amino acid zwitterion;
angiotensin II | human metabolite | 2000 | 2012 | 18.0 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| sb 203580 | | imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zm 241385 | | diamino-1,3,5-triazine | | 2006 | 2014 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-((4,5-bis(4-methoxyphenyl)-2-thiazoyl)carbonyl)-4-methylpiperazine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lilial | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| wortmannin | | acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound | anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent | 1996 | 2008 | 22.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| 5'-deoxyadenosine | | 5'-deoxyribonucleoside;
adenosines | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bradykinin | | oligopeptide | human blood serum metabolite;
vasodilator agent | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| oxytocin | | heterodetic cyclic peptide;
peptide hormone | oxytocic;
vasodilator agent | 2003 | 2012 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| inositol 1,4,5-trisphosphate | | myo-inositol trisphosphate | mouse metabolite | 1997 | 2011 | 21.8 | low | 0 | 0 | 2 | 2 | 1 | 0 |
| ouabain | | 11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone | anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite | 1993 | 2003 | 26.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| amastatin | | tetrapeptide | EC 3.4.11.* (aminopeptidase) inhibitor;
protease inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitroarginine | | guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid | | 2000 | 2008 | 21.3 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| ryanodine | | | | 1997 | 2005 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| bq 123 | | cyclic peptide | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-formylmethionine leucyl-phenylalanine | | tripeptide | | 1983 | 2001 | 30.2 | low | 0 | 1 | 2 | 1 | 0 | 0 |
| betadex | | cyclodextrin | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tretinoin | | retinoic acid;
vitamin A | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arachidonic acid | | icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid | Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite | 1984 | 2014 | 25.3 | low | 0 | 1 | 1 | 0 | 1 | 0 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thapsigargin | | butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone | calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor | 1996 | 2008 | 22.4 | low | 0 | 0 | 2 | 3 | 0 | 0 |
| y 27632 | | aromatic amide | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adenosine-5'-(n-ethylcarboxamide) | | adenosines;
monocarboxylic acid amide | adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 1987 | 2001 | 29.2 | low | 0 | 1 | 2 | 1 | 0 | 0 |
| prostaglandin d2 | | prostaglandins D | human metabolite;
mouse metabolite | 1984 | 2002 | 31.5 | low | 0 | 2 | 1 | 1 | 0 | 0 |
| h 89 | | N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide | | 1996 | 2019 | 19.1 | low | 0 | 0 | 8 | 11 | 8 | 0 |
| iridoids | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| kt 5720 | | carboxylic ester;
gamma-lactam;
hemiaminal;
indolocarbazole;
organic heterooctacyclic compound;
semisynthetic derivative;
tertiary alcohol | EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor | 1998 | 2018 | 18.9 | low | 0 | 0 | 3 | 7 | 1 | 0 |
| dactinomycin | | actinomycin | mutagen | 1996 | 2011 | 21.7 | low | 0 | 0 | 2 | 0 | 1 | 0 |
| trilostane | | 17beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile | abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| capsaicin | | capsaicinoid | non-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker | 2001 | 2004 | 21.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| chlorogenic acid | | cinnamate ester;
tannin | food component;
plant metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiourea | | one-carbon compound;
thioureas;
ureas | antioxidant;
chromophore | 2000 | 2008 | 20.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole | | benzoic acid;
imidazolines;
organic radical | apoptosis inhibitor;
radical scavenger | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2000 | 2009 | 19.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| u 0126 | | aryl sulfide;
dinitrile;
enamine;
substituted aniline | antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester | | | | 2006 | 2007 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 8-bromoguanosino-3',5'-cyclic monophosphorothioate | | | | 2005 | 2018 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| u-50488 | | dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine | analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| inositol 1,4,6-trisphosphate | | myo-inositol trisphosphate | | 2002 | 2002 | 22.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine | | adenosines;
dicarboxylic acid monoamide;
monocarboxylic acid | adenosine A2A receptor agonist;
anti-inflammatory agent | 2005 | 2014 | 16.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| sb 258585 | | piperazines | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tissue plasminogen activator | | alpha-amino acid | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 6-cyano-7-nitroquinoxaline-2,3-dione | | quinoxaline derivative | | 2005 | 2007 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| alizarin red s | | organic sodium salt;
organosulfonate salt | histological dye | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| d 609 | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sphingosine | | sphing-4-enine | human metabolite;
mouse metabolite | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dinoprostone | | prostaglandins E | human metabolite;
mouse metabolite;
oxytocic | 1990 | 2020 | 20.8 | low | 0 | 0 | 9 | 5 | 3 | 0 |
| dinoprost | | monocarboxylic acid;
prostaglandins Falpha | human metabolite;
mouse metabolite | 2004 | 2011 | 16.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| linoleic acid | | octadecadienoic acid;
omega-6 fatty acid | algal metabolite;
Daphnia galeata metabolite;
plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| calcitriol | | D3 vitamins;
hydroxycalciol;
triol | antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| leukotriene b4 | | dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid | human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| thromboxane a2 | | epoxy monocarboxylic acid;
thromboxanes A | mouse metabolite | 1984 | 2001 | 31.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| 8,11,14-eicosatrienoic acid | | fatty acid 20:3;
long-chain fatty acid | fungal metabolite;
human metabolite;
nutraceutical | 2001 | 2006 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| alprostadil | | prostaglandins E | anticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent | 1995 | 2020 | 18.6 | low | 0 | 0 | 2 | 2 | 1 | 0 |
| genistein | | 7-hydroxyisoflavones | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor | 2002 | 2008 | 19.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| galangin | | 7-hydroxyflavonol;
trihydroxyflavone | antimicrobial agent;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
plant metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| anandamide | | endocannabinoid;
N-acylethanolamine 20:4 | human blood serum metabolite;
neurotransmitter;
vasodilator agent | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| uf 021 | | isopropyl ester;
ketone;
prostaglandins Falpha | antiglaucoma drug;
antihypertensive agent;
prodrug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glyceryl 2-arachidonate | | 2-acylglycerol 20:4;
endocannabinoid | human metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| misoprostol | | | | 1995 | 1996 | 28.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| 16,16-dimethylprostaglandin e2 | | cyclopentanones;
monocarboxylic acid;
prostanoid;
secondary allylic alcohol | anti-ulcer drug;
gastrointestinal drug;
radiation protective agent | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 8-isoprostaglandin e2 | | cyclic ketone;
diol;
prostanoid;
secondary alcohol | bronchoconstrictor agent;
human metabolite;
rat metabolite;
vasoconstrictor agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| naloxone | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol | antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| morphine | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atosiban | | oligopeptide | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cicaprost | | monoterpenoid | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iloprost | | carbobicyclic compound;
monocarboxylic acid;
secondary alcohol | platelet aggregation inhibitor;
vasodilator agent | 1990 | 2008 | 25.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| 15-deoxy-delta(12,14)-prostaglandin j2 | | prostaglandins J | electrophilic reagent;
insulin-sensitizing drug;
metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| lysophosphatidic acid | | 1-acyl-sn-glycerol 3-phosphate | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| mdl 100907 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cytochalasin b | | cytochalasin;
lactam;
lactone;
organic heterotricyclic compound | actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor | 1983 | 2002 | 31.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| pd 123319 | | imidazopyridine | angiotensin receptor antagonist;
endothelin receptor antagonist;
vasoconstrictor agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| calyculin a | | | | 1997 | 2009 | 19.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| thromboxane a2, carbocyclic | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sq 29548 | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| kn 62 | | piperazines | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| sulprostone | | prostanoid | | 1996 | 2013 | 22.0 | low | 0 | 0 | 2 | 0 | 1 | 0 |
| 1-hydroxy-2,3,5-trimethoxyxanthene | | | | 2007 | 2007 | 17.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| ag 99 | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bay 11-7082 | | nitrile;
sulfone | apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid | | | | 2003 | 2014 | 16.6 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| cesium | | alkali metal atom | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| naltrexone | | cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound | antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cysteine | | cysteinium | fundamental metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enkephalin, ala(2)-mephe(4)-gly(5)- | | | | 2001 | 2008 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| guanabenz | | dichlorobenzene | | 1999 | 2013 | 18.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetrodotoxin | | azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid | animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker | 1997 | 2018 | 16.6 | low | 0 | 0 | 3 | 3 | 4 | 0 |
| carboprostacyclin | | prostanoid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| beta-escin | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| s-nitroso-n-acetylpenicillamine | | nitroso compound;
nitrosothio compound | nitric oxide donor;
vasodilator agent | 2006 | 2018 | 13.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sb 269970 | | sulfonamide | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adenosine-3',5'-cyclic phosphorothioate | | nucleoside 3',5'-cyclic phosphorothioate | | 1996 | 2013 | 22.2 | low | 0 | 0 | 6 | 3 | 2 | 0 |
| 8-bromo-beta-phenyl-1,n(2)-ethenoguanosine 3',5'-cyclic monophosphorothioate | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| beraprost | | enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol | anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent | 1993 | 2008 | 23.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| staurosporine | | ammonium ion derivative | | 1996 | 2005 | 23.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| 8-bromoadenosine-3',5'-cyclic monophosphorothioate | | | | 2003 | 2009 | 18.0 | low | 0 | 0 | 0 | 5 | 0 | 0 |
| kb r7943 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n(6)-cyclohexyladenosine | | | | 1987 | 2014 | 22.0 | low | 0 | 1 | 0 | 1 | 1 | 0 |
| brl 37344 | | monocarboxylic acid | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cangrelor | | adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound | P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| l 858051 | | | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| shu 9119 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 5-chloro-2-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole | | indoles | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxadiazoles | | | | 2000 | 2019 | 17.6 | low | 0 | 0 | 2 | 13 | 4 | 0 |
| ucn 1028 c | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| losartan potassium | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| calcimycin | | benzoxazole | | 1983 | 2001 | 29.0 | low | 0 | 1 | 2 | 1 | 0 | 0 |
| pituitrin | | | | 1985 | 1991 | 36.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| butaprost | | | | 1995 | 2020 | 18.6 | low | 0 | 0 | 2 | 2 | 1 | 0 |
| calcitonin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| atrial natriuretic factor | | polypeptide | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| gastrins | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glucagon | | peptide hormone | | 1991 | 2006 | 23.8 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| beta-endorphin | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| neuropeptide y | | | | 1996 | 2011 | 22.0 | low | 0 | 0 | 2 | 0 | 1 | 0 |
| peptide phi | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iberiotoxin | | | | 2004 | 2011 | 17.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| liraglutide | | lipopeptide;
polypeptide | glucagon-like peptide-1 receptor agonist;
neuroprotective agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glucagon-like peptide 1 | | | | 2003 | 2012 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vasoactive intestinal peptide (10-28) | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| endothelin-1 | | | | 1998 | 2005 | 22.2 | low | 0 | 0 | 2 | 3 | 0 | 0 |
| phosphatidylcholines | | 1,2-diacyl-sn-glycero-3-phosphocholine | | 2004 | 2006 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| bucladesine | | 3',5'-cyclic purine nucleotide | | 1996 | 2012 | 22.9 | low | 0 | 0 | 7 | 6 | 1 | 0 |
| picrotoxin | | | | 1999 | 2005 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| dolichol monophosphate | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cardiovascular agents | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 11,12-epoxy-5,8,14-eicosatrienoic acid | | 11,12-EET | human xenobiotic metabolite | 2001 | 2006 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| m&b 28,767 | | | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| piperidines | | | | 1999 | 2005 | 22.5 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| interleukin-8 | | | | 2009 | 2016 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| int-777 | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| vasoactive intestinal peptide | | | | 2000 | 2005 | 22.3 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| acth (7-38) | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| charybdotoxin | | | | 2004 | 2006 | 19.0 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| transforming growth factor beta | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclin d1 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tws 119 | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| angiotensin i | | angiotensin;
peptide zwitterion | human metabolite;
neurotransmitter agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adrenomedullin | | | | 2000 | 2013 | 18.7 | low | 0 | 0 | 1 | 5 | 1 | 0 |
| cyclic gmp | | 3',5'-cyclic purine nucleotide;
guanyl ribonucleotide | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1997 | 2020 | 17.1 | low | 0 | 0 | 2 | 14 | 5 | 0 |
| guanosine diphosphate | | guanosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate | Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanosine triphosphate | | guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate | Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor | 1988 | 2005 | 28.4 | low | 0 | 1 | 4 | 2 | 0 | 0 |
| guanosine | | guanosines;
purines D-ribonucleoside | fundamental metabolite | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| guanosine 5'-o-(3-thiotriphosphate) | | nucleoside triphosphate analogue | | 2000 | 2009 | 21.2 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| zaprinast | | triazolopyrimidines | | 2000 | 2002 | 23.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| guanylyl imidodiphosphate | | nucleoside triphosphate analogue | | 1986 | 2005 | 28.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| bl 4162a | | imidazoquinazoline | anticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| guanosine 5'-o-(2-thiodiphosphate) | | nucleoside diphosphate analogue | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 8-bromocyclic gmp | | 3',5'-cyclic purine nucleotide;
organobromine compound | muscle relaxant;
protein kinase G agonist | 2002 | 2020 | 15.8 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| dibutyryl cyclic gmp | | | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Abdominal Migraine | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Absence Seizure Disorder | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Ache | 0 | | 2009 | 2019 | 9.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Acute Disease | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Promyelocytic Leukemia | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Respiratory Distress Syndrome | 0 | | 1990 | 2003 | 27.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Age-Related Macular Degeneration | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Aging | 0 | | 2006 | 2010 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Albuminuria | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Allodynia | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Alloxan Diabetes | 0 | | 2012 | 2017 | 9.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Anoxemia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anxiety | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Asymmetric Diabetic Proximal Motor Neuropathy | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bladder Cancer | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Blood Clot | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Blood Poisoning | 0 | | 2001 | 2021 | 15.7 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| Blood Pressure, High | 0 | | 2000 | 2004 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Body Weight | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bone Loss, Osteoclastic | 0 | | 1987 | 1990 | 35.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Brain Inflammation | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Brain Ischemia | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cancer of Liver | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Lung | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Mouth | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carcinoma, Non-Small Cell Lung | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Non-Small-Cell Lung | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiac Failure | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cerebral Infarction, Middle Cerebral Artery | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cerebral Ischemia | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Chronic Disease | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Illness | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cirrhosis, Liver | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cognitive Decline | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cognitive Dysfunction | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Congenital Zika Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Coronary Disease | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Coronary Heart Disease | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Diabetic Glomerulosclerosis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diabetic Nephropathies | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diabetic Neuropathies | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diffuse Myofascial Pain Syndrome | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disease Models, Animal | 0 | | 2003 | 2020 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Elevated Cholesterol | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Encephalitis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Epilepsy, Absence | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Experimental Mammary Neoplasms | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fibromyalgia | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fundus Flavimaculatus | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Germinoblastoma | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Goldblatt Syndrome | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Granuloma | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Granulomas | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Heart Failure | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypercholesterolemia | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperprolactinaemia | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperprolactinemia | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypertension | 0 | | 2000 | 2004 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Hypertension, Renovascular | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypoxia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Infarction, Middle Cerebral Artery | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Inflammation | 0 | | 2001 | 2018 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Inflammation, Endodontic | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Innate Inflammatory Response | 0 | | 2001 | 2018 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Lesion of Sciatic Nerve | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leukemia, Acute Monocytic | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Leukemia, Lymphocytic, T Cell | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Leukemia, Monocytic, Acute | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Leukemia, Promyelocytic, Acute | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leukemia, T-Cell | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Liver Cirrhosis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Liver Neoplasms | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lung Neoplasms | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphoma | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Macular Degeneration | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Migraine Disorders | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Mouth Neoplasms | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Muscle Contraction | 0 | | 1986 | 2005 | 25.8 | low | 0 | 1 | 1 | 3 | 0 | 0 |
| Muscle Relaxation | 0 | | 1993 | 2012 | 19.9 | low | 0 | 0 | 4 | 7 | 3 | 0 |
| Nerve Pain | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neuralgia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pain | 0 | | 2009 | 2019 | 9.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Pericementitis | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Periodontitis | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Peripheral Nerve Diseases | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Peripheral Nervous System Diseases | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pregnancy | 0 | | 1995 | 2008 | 21.2 | low | 0 | 0 | 2 | 3 | 0 | 0 |
| Pulpitis | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Respiratory Distress Syndrome | 0 | | 1990 | 2003 | 27.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Retinal Diseases | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Sepsis | 0 | | 2001 | 2021 | 15.7 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| Skin Aging | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Stargardt Disease | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Thromboembolism | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Thrombosis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Urinary Bladder Neoplasms | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Zika Virus Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Anti-inflammatory effects of low-level laser therapy on human periodontal ligament cells: in vitro study.Lasers in medical science, , Volume: 33, Issue:3, 2018
Alcohol Decreases Organic Dust-Stimulated Airway Epithelial TNF-Alpha Through a Nitric Oxide and Protein Kinase-Mediated Inhibition of TACE.Alcoholism, clinical and experimental research, , Volume: 40, Issue:2, 2016
Calcitonin gene-related peptide mediates an inflammatory response in Schwann cells via cAMP-dependent ERK signaling cascade.Life sciences, , Jan-01, Volume: 144, 2016
Adrenomedullin suppresses fMLP-induced upregulation of CD11b of human neutrophils.Inflammation, , Volume: 25, Issue:3, 2001
Mechanisms underlying the inhibitory effects induced by pituitary adenylate cyclase-activating peptide in mouse ileum.European journal of pharmacology, , Oct-03, Volume: 521, Issue:1-3, 2005
Angiotensin II-induced relaxation of anococcygeus smooth muscle via desensitization of AT1 receptor, and activation of AT2 receptor associated with nitric-oxide synthase pathway.The Journal of pharmacology and experimental therapeutics, , Volume: 311, Issue:1, 2004
The roles of cyclic adenosine monophosphate- and cyclic guanosine monophosphate-dependent protein kinase pathways in hydrogen peroxide-induced contractility of microvascular lung pericytes.The Journal of trauma, , Volume: 55, Issue:4, 2003
Relaxation and inhibition of contractile response to electrical field stimulation by Beraprost sodium in canine airway smooth muscle.Prostaglandins, , Volume: 45, Issue:4, 1993
Relaxant effect of forskolin in rabbit detrusor smooth muscle: role of cyclic AMP.The Journal of urology, , Volume: 135, Issue:6, 1986
Multiple effects of gymnopilin on circulatory system of the rat.Biological & pharmaceutical bulletin, , Volume: 35, Issue:8, 2012
Characterization of P2Y receptors mediating ATP induced relaxation in guinea pig airway smooth muscle: involvement of prostaglandins and K+ channels.Pflugers Archiv : European journal of physiology, , Volume: 462, Issue:4, 2011
Ibudilast, a mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP-independent relaxation of the intracranial vertebrobasilar artery.European journal of pharmacology, , Jan-15, Volume: 650, Issue:2-3, 2011
Myosin light chain phosphatase activation is involved in the hydrogen sulfide-induced relaxation in mouse gastric fundus.European journal of pharmacology, , Mar-15, Volume: 606, Issue:1-3, 2009
Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol?The Journal of pharmacology and experimental therapeutics, , Volume: 313, Issue:1, 2005
Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via beta-adrenoceptors.European journal of pharmacology, , Aug-22, Volume: 518, Issue:2-3, 2005
Role of adenylate and guanylate cyclases in beta1-, beta2-, and beta3-adrenoceptor-mediated relaxation of internal anal sphincter smooth muscle.The Journal of pharmacology and experimental therapeutics, , Volume: 308, Issue:3, 2004
Angiotensin II-induced relaxation of anococcygeus smooth muscle via desensitization of AT1 receptor, and activation of AT2 receptor associated with nitric-oxide synthase pathway.The Journal of pharmacology and experimental therapeutics, , Volume: 311, Issue:1, 2004
Cyclic AMP-independent relaxation mediated by beta3-adrenoceptors on guinea pig gastrointestine.European journal of pharmacology, , May-03, Volume: 442, Issue:1-2, 2002
Comparative vasodilation of peroxynitrite and 3-morpholinosydnonimine.Life sciences, , Oct-05, Volume: 69, Issue:20, 2001
Interplay between nitric oxide and vasoactive intestinal polypeptide in the pig gastric fundus smooth muscle.European journal of pharmacology, , Jun-02, Volume: 397, Issue:2-3, 2000
Investigation of the interaction between nitric oxide and vasoactive intestinal polypeptide in the guinea-pig gastric fundus.British journal of pharmacology, , Volume: 129, Issue:4, 2000
Spontaneous photo-relaxation of urethral smooth muscle from sheep, pig and rat and its relationship with nitrergic neurotransmission.The Journal of physiology, , Feb-01, Volume: 522 Pt 3, 2000
Relaxation and inhibition of contractile response to electrical field stimulation by Beraprost sodium in canine airway smooth muscle.Prostaglandins, , Volume: 45, Issue:4, 1993
The pronociceptive role of 5-HTNeurochemistry international, , Volume: 131, 2019
Inhibition of Adenylyl Cyclase in the Spinal Cord Alleviates Painful Diabetic Neuropathy in Zucker Diabetic Fatty Rats.Canadian journal of diabetes, , Volume: 41, Issue:2, 2017
Adenylate cyclase inhibition attenuates neuropathic pain but lacks pre-emptive effects in rats.Canadian journal of anaesthesia = Journal canadien d'anesthesie, , Volume: 56, Issue:10, 2009
cAMP promotes neurite outgrowth and extension through protein kinase A but independently of Erk activation in cultured rat motoneurons.Neuropharmacology, , Volume: 55, Issue:1, 2008
Cyclic AMP-independent CGRP8-37-sensitive receptors mediate adrenomedullin-induced decrease of CaCl2-contraction in pregnant rat mesenteric artery.Journal of vascular research, , Volume: 45, Issue:1, 2008
Effects of recombinant human relaxin on pregnant rat uterine artery and myometrium in vitro.American journal of obstetrics and gynecology, , Volume: 188, Issue:6, 2003
Role of nucleotide cyclases in the inhibition of pregnant rat uterine contractions by the openers of potassium channels.American journal of obstetrics and gynecology, , Volume: 182, Issue:4, 2000
The controversial role of cAMP on amnionic prostaglandin release: effect of adenylate cyclase inhibition.Gynecologic and obstetric investigation, , Volume: 40, Issue:2, 1995
INT-777 prevents cognitive impairment by activating Takeda G protein-coupled receptor 5 (TGR5) and attenuating neuroinflammation via cAMP/ PKA/ CREB signaling axis in a rat model of sepsis.Experimental neurology, , Volume: 335, 2021
The roles of cyclic adenosine monophosphate- and cyclic guanosine monophosphate-dependent protein kinase pathways in hydrogen peroxide-induced contractility of microvascular lung pericytes.The Journal of trauma, , Volume: 55, Issue:4, 2003
cAMP inhibits inducible nitric oxide synthase expression and NF-kappaB-binding activity in cultured rat hepatocytes.The Journal of surgical research, , Volume: 99, Issue:2, 2001
INT-777 prevents cognitive impairment by activating Takeda G protein-coupled receptor 5 (TGR5) and attenuating neuroinflammation via cAMP/ PKA/ CREB signaling axis in a rat model of sepsis.Experimental neurology, , Volume: 335, 2021
The roles of cyclic adenosine monophosphate- and cyclic guanosine monophosphate-dependent protein kinase pathways in hydrogen peroxide-induced contractility of microvascular lung pericytes.The Journal of trauma, , Volume: 55, Issue:4, 2003
cAMP inhibits inducible nitric oxide synthase expression and NF-kappaB-binding activity in cultured rat hepatocytes.The Journal of surgical research, , Volume: 99, Issue:2, 2001
Inhibition of Adenylyl Cyclase in the Spinal Cord Alleviates Painful Diabetic Neuropathy in Zucker Diabetic Fatty Rats.Canadian journal of diabetes, , Volume: 41, Issue:2, 2017
Vasodilator Effects of Elcatonin, a Synthetic Eel Calcitonin, on Retinal Blood Vessels in Rats.Biological & pharmaceutical bulletin, , Volume: 38, Issue:10, 2015
GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.Metabolism: clinical and experimental, , Volume: 61, Issue:10, 2012
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020
Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration.The Journal of clinical investigation, , Volume: 123, Issue:12, 2013
Increase nitric oxide synthase activity in parotid glands from rats with experimental periodontitis.Oral diseases, , Volume: 16, Issue:8, 2010
Impaired regulation of thalamic pacemaker channels through an imbalance of subunit expression in absence epilepsy.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Oct-26, Volume: 25, Issue:43, 2005
Phosphorylation of CREB and mechanical hyperalgesia is reversed by blockade of the cAMP pathway in a time-dependent manner after repeated intramuscular acid injections.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Jul-02, Volume: 23, Issue:13, 2003
Anti-inflammatory effects of low-level laser therapy on human periodontal ligament cells: in vitro study.Lasers in medical science, , Volume: 33, Issue:3, 2018
Alcohol Decreases Organic Dust-Stimulated Airway Epithelial TNF-Alpha Through a Nitric Oxide and Protein Kinase-Mediated Inhibition of TACE.Alcoholism, clinical and experimental research, , Volume: 40, Issue:2, 2016
Calcitonin gene-related peptide mediates an inflammatory response in Schwann cells via cAMP-dependent ERK signaling cascade.Life sciences, , Jan-01, Volume: 144, 2016
Adrenomedullin suppresses fMLP-induced upregulation of CD11b of human neutrophils.Inflammation, , Volume: 25, Issue:3, 2001
The pronociceptive role of 5-HTNeurochemistry international, , Volume: 131, 2019
Inhibition of Adenylyl Cyclase in the Spinal Cord Alleviates Painful Diabetic Neuropathy in Zucker Diabetic Fatty Rats.Canadian journal of diabetes, , Volume: 41, Issue:2, 2017
Adenylate cyclase inhibition attenuates neuropathic pain but lacks pre-emptive effects in rats.Canadian journal of anaesthesia = Journal canadien d'anesthesie, , Volume: 56, Issue:10, 2009
Safety/Toxicity (2)
Bioavailability (1)
Dosage (1)